Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging - PubMed (original) (raw)
. 2011 Sep;197(3):664-70.
doi: 10.2214/AJR.10.5923.
Affiliations
- PMID: 21862809
- DOI: 10.2214/AJR.10.5923
Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging
Tsutomu Tamada et al. AJR Am J Roentgenol. 2011 Sep.
Abstract
Objective: The purpose of this study is to evaluate the utility of T2-weighted imaging, dynamic contrast-enhanced MRI (DCE-MRI), and diffusion-weighted imaging (DWI) for detecting prostate cancer in patients with total serum prostate-specific antigen (PSA) levels of 4-10 ng/mL, which is referred to as the "gray zone."
Materials and methods: Fifty patients with gray-zone PSA levels underwent MRI before biopsy. According to the sites of biopsy, the prostate was divided into eight regions on MRI scans. These regions were evaluated individually for the following features: detectability of prostate cancer on per-region and per-patient bases, and relationship between tumor size and positive or negative MRI findings for tumor detection.
Results: On a per-region basis, the sensitivity and specificity of tumor detection were 36% and 97% for T2-weighted imaging, 43% and 95% for DCE-MRI, 38% and 96% for DWI, and 53% and 93% for the combined method of MRI, respectively. The sensitivity of combined MRI to detect tumor was significantly higher than those of the individual methods (p < 0.001 to p = 0.001). Tumor size was significantly larger in regions with positive MRI findings than in regions with negative MRI findings (p = 0.004). On a per-patient basis, sensitivity and specificity of combined MRI to detect prostate cancer were 83% and 80%, respectively.
Conclusion: Combined T2-weighted imaging, DWI, and DCE-MRI findings appear to be potentially useful for detecting and managing prostate cancer, even when performed for patients with gray-zone PSA levels.
Similar articles
- Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors.
Tamada T, Sone T, Jo Y, Hiratsuka J, Higaki A, Higashi H, Ito K. Tamada T, et al. AJR Am J Roentgenol. 2011 Aug;197(2):408-14. doi: 10.2214/AJR.10.5772. AJR Am J Roentgenol. 2011. PMID: 21785087 - Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer.
Vilanova JC, Barceló-Vidal C, Comet J, Boada M, Barceló J, Ferrer J, Albanell J. Vilanova JC, et al. AJR Am J Roentgenol. 2011 Jun;196(6):W715-22. doi: 10.2214/AJR.10.5700. AJR Am J Roentgenol. 2011. PMID: 21606259 - Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings.
Aydin H, Kizilgöz V, Tatar IG, Damar C, Ugan AR, Paker I, Hekimoğlu B. Aydin H, et al. J Comput Assist Tomogr. 2012 Jan-Feb;36(1):30-45. doi: 10.1097/RCT.0b013e31823f6263. J Comput Assist Tomogr. 2012. PMID: 22261768 - The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.
Lawrentschuk N, Fleshner N. Lawrentschuk N, et al. BJU Int. 2009 Mar;103(6):730-3. doi: 10.1111/j.1464-410X.2008.08205.x. Epub 2009 Jan 14. BJU Int. 2009. PMID: 19154475 Review. - [MRI for troubleshooting detection of prostate cancer].
Beyersdorff D, Hamm B. Beyersdorff D, et al. Rofo. 2005 Jun;177(6):788-95. doi: 10.1055/s-2005-858151. Rofo. 2005. PMID: 15902626 Review. German.
Cited by
- Functional and molecular imaging of localized and recurrent prostate cancer.
Grant K, Lindenberg ML, Shebel H, Pang Y, Agarwal HK, Bernardo M, Kurdziel KA, Turkbey B, Choyke PL. Grant K, et al. Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1(Suppl 1):S48-59. doi: 10.1007/s00259-013-2419-6. Epub 2013 May 7. Eur J Nucl Med Mol Imaging. 2013. PMID: 23649462 Free PMC article. Review. - Prostate imaging features that indicate benign or malignant pathology on biopsy.
Lovegrove CE, Matanhelia M, Randeva J, Eldred-Evans D, Tam H, Miah S, Winkler M, Ahmed HU, Shah TT. Lovegrove CE, et al. Transl Androl Urol. 2018 Sep;7(Suppl 4):S420-S435. doi: 10.21037/tau.2018.07.06. Transl Androl Urol. 2018. PMID: 30363462 Free PMC article. Review. - Implementation of Multi-parametric Prostate MRI in Clinical Practice.
Kierans AS, Taneja SS, Rosenkrantz AB. Kierans AS, et al. Curr Urol Rep. 2015 Aug;16(8):56. doi: 10.1007/s11934-015-0530-x. Curr Urol Rep. 2015. PMID: 26077358 Review. - The value of diffusion-weighted imaging in the detection of prostate cancer: a meta-analysis.
Jie C, Rongbo L, Ping T. Jie C, et al. Eur Radiol. 2014 Aug;24(8):1929-41. doi: 10.1007/s00330-014-3201-2. Epub 2014 May 28. Eur Radiol. 2014. PMID: 24865693 Free PMC article. Review. - Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men.
Pahwa S, Schiltz NK, Ponsky LE, Lu Z, Griswold MA, Gulani V. Pahwa S, et al. Radiology. 2017 Oct;285(1):157-166. doi: 10.1148/radiol.2017162181. Epub 2017 May 17. Radiology. 2017. PMID: 28514203 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous